ArticleCurrent pharmaceutical biotechnology2025
DDP Induced Cytotoxicity through miR-215-5p/COL5A1/FSTL1 Axis to Regulate Autophagy in Lung Adenocarcinoma Cells.
Article in Current pharmaceutical biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- SPARC family proteins: matricellular modulators of cancer progression and therapeutic resistance.Cancer gene therapy · 2026Review
- Role of autophagy in tumorigenesis and drug resistance: molecular mechanisms and therapeutic targets.Molecular biomedicine · 2026Review
- miR-215-5p Suppresses Proliferation/Cell-Cycle Progression and Promotes Apoptosis via Targeting CTCF in Goat Mammary Epithelial Cells.Animals : an open access journal from MDPI · 2026Article
- Integrative Multiomics Analysis Identifies a Novel Gene Signature That Predicts Chemotherapy Resistance and Poor Survival in Osteosarcoma.Human mutation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCisplatin (DDP) resistance remains a major challenge in the treatment of lung adenocarcinoma (LUAD). Autophagy is an important mechanism to generate drug resistance. It has been established that COL5A1 has been shown to accelerate LUAD metastasis and affect cellular processes.
methodsWe investigated the role of COL5A1 in DDP resistance using the H1299/DDP and A549/DDP cell lines. Flow cytometry, CCK8, and western blot assays were used to detect apoptosis, cell viability, and autophagy. In addition, upstream miRNAs were screened using bioinformatics methods. MS2-RIP assay and luciferase reporter gene assay were used to validate miRNA interaction with COL5A1. Transfection experiments and western blot experiments were performed to investigate miRNA targeting to COL5A1 and its regulation of autophagy through FSTL1. The role of miRNA and COL5A1 in LUAD cisplatin resistance was also verified
resultsThe down-regulation of COL5A1 significantly reduced the survival and autophagy of DDP-resistant cells while enhancing apoptosis. MiR-215-5p was found to be a direct regulator of COL5A1, which affects autophagy through FSTL1.
conclusionThe present study demonstrated that miR-215-5p regulated COL5A1 to modulate FSTL1 and autophagy, thereby attenuating LUAD resistance to DDP. These findings deepen the understanding of LUAD pathogenesis and provide potential insights into therapeutic strategies.
Indexed as
Identifiers
39289933What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.